Mental health is on the decline all over the world.
At the moment, nearly 264 million people are struggling with depression, for example.
To help alleviate the symptoms of depression, many turn to anti-depressants such as SSRIs (selective serotonin reuptake inhibitors). Problem is — SSRIs aren’t always useful, focusing more on symptom suppression than root cause. Of course, that needs to change. That being said, the pharmaceutical industry is overdue for a massive, game-changing revolution when it comes to mental health care.
Fortunately, the revolution has already begun with the study of psilocybin. This could be significant news for companies such as Lexston Life Sciences Corp. (CSE:LEXT)(OTCQB:LEXTF), Mind Medicine (NASDAQ:MNMD)(NEO:MMED), COMPASS Pathways (NASDAQ:CMPS), Field Trip Health Ltd. (TSX:FTRP)(NASDAQ:FTRP), and Cybin Inc. (NEO:CYBN)(NYSE:CYBN).
Even better, as noted by NPR, a study from JAMA Psychiatry recently found that psilocybin “worked better than the usual antidepressant medications.” Even a study in the journal, Nature — “psilocybin for treatment-resistant depression: fMRI-measure brain mechanisms” – showed that around 47% of patients with treatment-resistant-depression showed positive responses approximately five weeks after psilocybin treatments.”